{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:04:17Z","timestamp":1770073457492,"version":"3.49.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Carbapenemase-producing <jats:italic>Klebsiella pneumoniae<\/jats:italic> infections are an increasing global threat with scarce and uncertain treatment options. In this context, combination therapies are often used for these infections. The bactericidal and synergistic activity of fosfomycin plus amikacin and gentamicin was studied trough time\u2013kill assays against four clonally unrelated clinical isolates of carbapenemase-producing <jats:italic>K. pneumoniae<\/jats:italic>, VIM-1, VIM-1 plus DHA-1, OXA-48 plus CTXM-15, and KPC-3, respectively. The efficacy of antimicrobials that showed synergistic activity <jats:italic>in vitro<\/jats:italic> against all the carbapenemase-producing <jats:italic>K. pneumoniae<\/jats:italic> were tested in monotherapy and in combination, in a murine peritoneal sepsis model. <jats:italic>In vitro<\/jats:italic>, fosfomycin plus amikacin showed synergistic and bactericidal effect against strains producing VIM-1, VIM-1 plus DHA-1, and OXA-48 plus CTX-M-15. Fosfomycin plus gentamicin had <jats:italic>in vitro<\/jats:italic> synergistic activity against the strain producing KPC-3. <jats:italic>In vivo<\/jats:italic>, fosfomycin and amikacin and its combination reduced the spleen bacterial concentration compared with controls groups in animals infected by <jats:italic>K. pneumoniae<\/jats:italic> producing VIM-1 and OXA-48 plus CTX-M-15. Moreover, amikacin alone and its combination with fosfomycin reduced the bacteremia rate against the VIM-1 producer strain. Contrary to the <jats:italic>in vitro<\/jats:italic> results, no <jats:italic>in vivo<\/jats:italic> efficacy was found with fosfomycin plus amikacin against the VIM-1 plus DHA-1 producer strain. Finally, fosfomycin plus gentamicin reduced the bacterial concentration in spleen against the KPC-3 producer strain. In conclusion, our results suggest that fosfomycin plus aminoglycosides has a dissimilar efficacy in the treatment of this severe experimental infection, when caused by different carbapenemase-producing <jats:italic>K. pneumoniae<\/jats:italic> strains. Fosfomycin plus amikacin or plus gentamycin may be useful to treat infections by OXA-48 plus CTX-M-15 or KPC-3 producer strains, respectively.<\/jats:p>","DOI":"10.3389\/fmed.2021.615540","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T06:36:01Z","timestamp":1616740561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing Klebsiella pneumoniae Clinical Strains"],"prefix":"10.3389","volume":"8","author":[{"given":"Tania","family":"Cebrero-Cangueiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Labrador-Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caridad","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jer\u00f3nimo","family":"Pach\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 P.","family":"del Palacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda E.","family":"Pach\u00f3n-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Carmen","family":"Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/jac\/dkv294","article-title":"In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae","volume":"71","author":"Poirel","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"B2","volume-title":"Principles and Practice of Infectious Disease","author":"Mandell","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"179.e1","DOI":"10.1016\/j.cmi.2014.07.010","article-title":"Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins","volume":"21","author":"de Oliveira","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1089\/mdr.2019.0498","article-title":"Investigation of the in vitro effectiveness of aztreonam\/avibactam, colistin\/apramycin, and meropenem\/apramycin combinations against carbapenemase-producing, extensively drug-resistant Klebsiella pneumoniae strains","volume":"26","author":"Kilic","year":"2020","journal-title":"Microbial Drug Resist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13756-020-00727-4","article-title":"In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains","volume":"9","author":"Erdem","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"B8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cmi.2019.04.013","article-title":"Management of carbapenem-resistant Enterobacteriaceae infections","volume":"25","author":"Durante-Mangoni","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"B9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","article-title":"Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options","volume":"10","author":"Sheu","year":"2019","journal-title":"Front Microbiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e00079","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodriguez-Bano","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-producing organisms: a global scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.cmi.2020.03.007","article-title":"Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments","volume":"26","author":"Wistrand-Yuen","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jiac.2019.10.014","article-title":"In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains","volume":"26","author":"Hagihara","year":"2020","journal-title":"J Infect Chemother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"106152","DOI":"10.1016\/j.ijantimicag.2020.106152","article-title":"Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis","volume":"56","author":"Tattevin","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"B15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijantimicag.2017.03.011","article-title":"In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae","volume":"50","author":"Yu","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1128\/AAC.01086-10","article-title":"In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development","volume":"55","author":"Souli","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1093\/jac\/dkz257","article-title":"Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae","volume":"74","author":"Cremieux","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3389\/fmicb.2018.00912","article-title":"Efficacy of colistin and its combination with rifampin in vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of Klebsiella pneumoniae","volume":"9","author":"Pachon-Ibanez","year":"2018","journal-title":"Front Microbiol"},{"key":"B19","volume-title":"Performance Standars for Antimicrobial Susceptibility Tests.","year":"2019"},{"key":"B20","volume-title":"European Society of Clinical Microbiology and Infectious Diseases. Clinical Breakpoints","author":"(EUCAST)","year":"2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","article-title":"Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay","volume":"37","author":"Pournaras","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1093\/jac\/dky343","article-title":"Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: mechanistic analysis and in vivo efficacy","volume":"73","author":"Parra-Millan","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B23","article-title":"Committee on Care and Use of Laboratory Animals","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"US","year":"2011"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1128\/AAC.01367-09","article-title":"Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Gobin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1002\/jps.21317","article-title":"Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding","volume":"97","author":"Waters","year":"2008","journal-title":"J Pharm Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cmi.2018.02.005","article-title":"Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli","volume":"24","author":"Merino-Bohorquez","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1093\/jac\/dky283","article-title":"Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli","volume":"73","author":"Berleur","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1128\/AAC.02583-12","article-title":"Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model","volume":"58","author":"Oliva","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e00476","DOI":"10.1128\/AAC.00476-17","article-title":"In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13613-020-00685-5","article-title":"Amikacin pharmacokinetic\/pharmacodynamic in intensive care unit: a prospective database","volume":"10","author":"Logre","year":"2020","journal-title":"Ann Intensive Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/FTD.0000000000000800","article-title":"Impact of therapeutic drug monitoring on once-daily regimen of amikacin in patients with urinary tract infection: a prospective observational study","volume":"42","author":"Jayakumar","year":"2020","journal-title":"Ther Drug Monit"},{"key":"B35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jac\/dku341","article-title":"Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo-beta-lactamase-producing Klebsiella oxytoca","volume":"70","author":"Vergara-Lopez","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/jac\/dkp224","article-title":"Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model","volume":"64","author":"Cai","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1099\/jmm.0.000649","article-title":"In vitro and in vivo activity of fosfomycin alone and in combination with rifampin and tigecycline against Gram-positive cocci isolated from surgical wound infections","volume":"67","author":"Simonetti","year":"2018","journal-title":"J Med Microbiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.615540\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T06:36:06Z","timestamp":1616740566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.615540\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":38,"alternative-id":["10.3389\/fmed.2021.615540"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.615540","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"article-number":"615540"}}